Bush Intercontinental has seen a massive drop in travelers since the pandemic. Photo courtesy of Houston Airport System

Since the World Health Organization announced the COVID-19 as a global pandemic on March 11, few industries have slowed as dramatically as air travel. Airlines made massive cuts in services and jockeyed for government assistance. Some, such as United, announced furloughs of up to 45 percent of its U.S. based workers, some 36,000 employees.

Local airports such as George Bush Intercontinental witnessed a staggering drop in travelers.

Just how bad is the hit? Finance website FinanceBuzz crunched the numbers from the U.S. Bureau of Transportation to determine the pandemic's effect on the 30 busiest airports in the nation. The site examined the number of departing passengers on domestic flights from June 2019 and compared them to June of this year.

Houston's Bush Intercontinental (IAH) saw a dramatic decrease in traffic of 82.83 percent, according to FinanceBuzz. June 2019 saw 1,473,575 departing passengers, compared to just 253,036 in June of this year. That drop puts IAH at No. 13 in the top 15 airports with the biggest traffic drops in the U.S.

For some perspective, the airport with the biggest plunge is New York City's LaGuardia, which saw 1,281,848 travelers depart in June 2019, while a paltry 133,272 departed this June, for a 89.60 percent drop.

But it's not all gloom and doom for Texas airports. FinanceBuzz also looked at airports making the best recovery from April to June of this year. Overall, Dallas-Fort Worth International Airport saw the biggest increase in departing passengers, with 190,038 flying out in April 2020 and a whopping 998,875 flying out in June, for a jump of 425.62 percent.

The airport with the fastest recovery? That title goes to Chicago Midway International Airport, which saw 30,693 departures in April and 338,884 in June, for a leap of 1004.11 percent.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.